Loading...
EVLO

Evelo Biosciences, Inc.OTCPK:EVLO Stock Report

Market Cap US$18.0
Share Price
n/a
1Y-99.8%
7D0%
1D-99.0%
Portfolio Value
​
View

Evelo Biosciences, Inc.

OTCPK:EVLO Stock Report

Market Cap: US$18.0

Evelo Biosciences (EVLO) Stock Overview

A clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. More details

EVLO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap ($18)

Shares are highly illiquid

Latest financial reports are more than a year old


EVLO Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW444,159 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
444,159 investors already sharing narratives
View all narratives

Evelo Biosciences, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Evelo Biosciences
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$0.0005
52 Week LowUS$0.000001
Beta0
1 Month Change-99.00%
3 Month Change-99.00%
1 Year Change-99.80%
3 Year Change-99.90%
5 Year Change-99.90%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Analysis Article • Aug 18

Is Evelo Biosciences (NASDAQ:EVLO) Using Debt In A Risky Way?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Aug 11

Evelo Biosciences GAAP EPS of -$0.40 beats by $0.03

Evelo Biosciences press release (NASDAQ:EVLO): Q2 GAAP EPS of -$0.40 beats by $0.03. As of June 30, 2022, cash and cash equivalents were $92.0M, as compared to cash and cash equivalents of $68.4M as of December 31, 2021.
Seeking Alpha • Jul 18

Marella Thorell is the new finance chief of Evelo Biosciences

Evelo Biosciences (NASDAQ:EVLO) appoints 25 years of finance and operations experienced Marella Thorell as CFO, effective September 1, 2022. Most recently she served as Chief Accounting Officer and previously as Head of Finance of Centessa Pharmaceuticals.
Seeking Alpha • Jun 06

Evelo Biosciences: Hope After Dilution?

Today, we put Evelo Biosciences in the spotlight for the first time. The company has several potential catalysts on the horizon. The company also recently executed a large direct offering and brought aboard some strategic advisors as well. A full investment analysis follows in the paragraphs below.
Analysis Article • Mar 21

Evelo Biosciences (NASDAQ:EVLO) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article • Sep 25

Is Evelo Biosciences (NASDAQ:EVLO) Weighed On By Its Debt Load?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Mar 11

What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry?

If you want to know who really controls Evelo Biosciences, Inc. ( NASDAQ:EVLO ), then you'll have to look at the makeup...
Analysis Article • Dec 15

Trade Alert: The Independent Chairman Of Evelo Biosciences, Inc. (NASDAQ:EVLO), David Epstein, Has Just Spent US$51k Buying 77% More Shares

Whilst it may not be a huge deal, we thought it was good to see that the Evelo Biosciences, Inc. ( NASDAQ:EVLO...
Analysis Article • Dec 11

Do Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?

A look at the shareholders of Evelo Biosciences, Inc. ( NASDAQ:EVLO ) can tell us which group is most powerful. Large...

Shareholder Returns

EVLOUS BiotechsUS Market
7D0%-3.9%-1.5%
1Y-99.8%40.0%13.3%

Return vs Industry: EVLO underperformed the US Biotechs industry which returned 38% over the past year.

Return vs Market: EVLO underperformed the US Market which returned 13.9% over the past year.

Price Volatility

Is EVLO's price volatile compared to industry and market?
EVLO volatility
EVLO Average Weekly Movementn/a
Biotechs Industry Average Movement9.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: EVLO's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine EVLO's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/an/an/a

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology.

Evelo Biosciences, Inc. Fundamentals Summary

How do Evelo Biosciences's earnings and revenue compare to its market cap?
EVLO fundamental statistics
Market capUS$18.00
Earnings (TTM)-US$82.35m
Revenue (TTM)n/a
0.0x
P/S Ratio
0.0x
P/E Ratio

Is EVLO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EVLO income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$82.35m
Earnings-US$82.35m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did EVLO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/15 10:40
End of Day Share Price 2026/09/02 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evelo Biosciences, Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew LuchiniBMO Capital Markets Equity Research
Gary NachmanBMO Capital Markets Equity Research
Clarence PowellBMO Capital Markets Equity Research